KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting.

Maria A V Marzolini, Wendi Qian, Laura Clifton-Hadley, Pip Patrick, June Warden, Lindsey Stevens, Christopher F E Pocock, Fiona Miall, David Cunningham, Richard Stephens, Jan Walewski, Amanda Johnston, John F Seymour, David C Linch, Kirit M Ardeshna

Br J Haematol 206(3) 876-886

PMID39604791
PMCID-
DOI10.1111/bjh.19918
发表日期2024-11-28
入排依据:This is a randomized Phase III oncology trial with a drug intervention, but the primary endpoint is quality-of-life, not a time-to-event efficacy endpoint (OS, PFS, etc.) as required. Therefore, it is excluded.
摘要

摘要

Traditionally, patients with asymptomatic, advanced-stage follicular lymphoma were managed with a watchful-waiting approach until disease progression. The 'Watch and Wait' Phase-3 randomised international trial examined whether rituximab could delay the need for treatment and the effect on quality of life (QoL). In this article, we present the long-term results of the QoL aspect of the trial. Patients were randomised to watchful-waiting (Arm A), rituximab induction (Arm B) or rituximab induction followed by maintenance (Arm C). We present the QoL outcomes from 180 patients (Arm A), 188 patients (Arm C) and an exploratory analysis of 82 (Arm B) compared to 81 and 84 patients concurrently randomised to arms A and C. Arm C reported greater improvement in emotional well-being overtime (Month 37, p = 0.0078) and were significantly more likely to feel in control of their situation than watchful-waiting patients (Month 25, p = 0.0004; Month 37, p = 0.0476). Watchful-waiting patients were significantly more likely to avoid thinking about their illness, did not find learning about their illness helped them and were more likely to attach unpleasant connotations to clinic visits (Month 7, p = 0.0032; Month 13, p = 0.0015; Month 25, p = 0.0104). These results demonstrate improved QoL scores in the induction and maintenance rituximab arm, indicating that rituximab was not detrimental to QoL and resulted in an improved QoL in some domains.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。